NCT00004478

Droxidopa in Treating Patients With Neurogenic Hypotension

Study of Droxidopa in Patients With Neurologic Hypotension

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: —
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Please note that the continuation study can be found at http://clinicaltrials.gov/show/NCT00633880. RATIONALE: Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position or after eating a meal. It causes one to feel dizzy, light headed, and weak. Neurogenic hypotension is caused by a problem in the part of the nervous system that controls such functions as heart rate and blood pressure. Droxidopa, a drug that may increase blood pressure, may be an effective treatment for neurogenic hypotension. PURPOSE: Clinical trial to study the effectiveness of droxidopa in treating patients who have neurogenic hypotension.

Detailed description

PROTOCOL OUTLINE: Patients receive escalating doses of droxidopa or placebo for 7-14 days. Patients undergo blood pressure measurements hourly in both supine and standing positions.

Conditions

• Shy-Drager Syndrome
• Orthostatic Hypotension

Interventions

Type	Name	Description
DRUG	droxidopa

Timeline

• Start date: 1999-03-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 1999-10-19
• Last updated: 2008-09-18

Locations

1 site across 1 country: United States